Treatment with atorvastatin reduces serum adipocyte‐fatty acid binding protein value in patients with hyperlipidaemia

Abstract

In conclusion, our study confirmed in vivo that atorvastatin reduces serum A-FABP by a pleiotropic mechanism and supports the hypothesis that A-FABP is involved in atherosclerotic actions.